CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

By Foo Yun Chee and Maggie Fick BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...

And please do keep in touch. … European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ ...

Catalent Inc ( (CTLT)) has released its Q1 earnings. Here is a breakdown of the information Catalent Inc presented to its investors. Catalent Inc., a leading global contract development and ...

Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...

(Reuters) - Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

Ardena, a Belgium-based pharmaceutical contract manufacturer, will acquire Catalent’s facility in Somerset, New Jersey, ...

EU antitrust regulators to decide on Novo Holdings' Catalent buy by Dec. 6 Novo announced $16.5 billion acquisition in February Novo Nordisk seeking to boost output of Wegovy weight-loss drug ...